Skip to main content
AmigoFish

Why Western pharma is sleeping on China's circular RNA revolution

From Beyond Biotech - the podcast from Labiotech · · 36 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA.

CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of English-language press coverage, until now.

My guest today is Dr. Lu Gao, CEO of Therorna Inc., a clinical-stage biotech headquartered in Beijing and Shanghai. The company recently presented three posters at ASGCT in Boston, and their lead program has just entered a first-in-human trial. We're going to talk about the science, the clinical strategy, and why Western pharma hasn't paid enough attention to what's being built in China.

- 01:33 Meet Lu Gao and Therorna

- 09:29 How Therorna's approach differs

- 15:42 How TI-0032 reprograms T cells in the body

- 21:22 Off-the-shelf and re-dosable: what it means for patients

- 24:38 Why no Chinese biotech has landed a major in vivo deal

- 31:27 What a successful US IND clearance would mean

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)

Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)

To dive deeper into the topic:

- The therapeutic potential of circular RNA: Could it soon trump mRNA technology? (https://www.labiotech.eu/in-depth/circular-rna/)

- mRNA, RNAi, circRNA, ASOs: A comparative guide to RNA therapeutics (https://www.labiotech.eu/in-depth/rna-therapeutics-review/)

- Therorna funding to accelerate circRNA-based platform (https://www.labiotech.eu/trends-news/biotech-circrna-covid/)

Back to Beyond Biotech - the podcast from Labiotech · Report a problem